Total Voting Rights

RNS Number : 8252G
ConvaTec Group PLC
31 March 2022
 

ConvaTec Group Plc ("the Company") - Total Voting Rights

Reading, United Kingdom (31 March 2022)

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 March 2022, the Company's issued capital with voting rights consisted of 2,034,572,935 ordinary shares of 10p each ('Shares'). The Company does not hold any Shares in Treasury at the date of this disclosure.

The above figure ( 2,034,572,935) can be used by shareholders as the denominator for the calculations by which to determine if they are required to notify their interest in, or a change to, their interest in the Company under the UK Financial Conduct Authority's Disclosure and Transparency Rules. 

 

Enquiries:

Analysts and Investors

Kate Postans, Vice President, Investor Relations   +44 (0)7826 447 807

ir@convatec.com

 

Media

Buchanan: Charles Ryland/Chris Lane        +44 (0)207 466 5000  

 

 

ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92

 

About ConvaTec

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. Our vision, which encompasses our purpose, is: Pioneering trusted medical solutions to improve the lives we touch. Our products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit  www.convatecgroup.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRMZGFFDMNGZZM
UK 100

Latest directors dealings